2020 OCT



Osteoporosis is a bone disease where the bone mass’ density decrease. Bones become more porous, number and size of the existing cavities inside them increases, making them more fragile and less resistant to blows, and consequently they break more easily.



Many metabolic changes occur throughout life inside our bones, alternating phases of destruction and bone formation.

Under normal conditions, a person reaches a maximum amount of bone mass at 30-35 years. From that moment on, there is a natural loss of bone mass. This physiological process is closely linked to aging and particularly to menopause.



Several studies show that Vitamin K may play an important role in the prevention or slowing natural mass bone loss, as well as fractures in postmenopausal women with osteoporosis. Menatetrenone is the brand name of a synthetic Vitamin K2 that is chemically identical to menaquinone-4.

According to American Bone Health TMVitamin K2 appears to protect the bones more than Vitamin K1, but too little of either is bad for the bones. Studies have shown that poor Vitamin K intake is linked to low bone mass, osteoporosis and fracture risk. Women who consumed less than 109 mcg of Vitamin K per day were found to be more likely to break a hip. Low vitamin K intake has also been linked to increased risk of hip fractures in men and women and to low bone density in women.

MENADIONA is a reliable manufacturer of Vitamin K in their forms of Vitamin K1 and Vitamin K2 (MK4 and MK7).

< >